| POXEL Stock | | | EUR 0.19 0.02 9.52% |
CFO
Ms. Anne Renevot was Chief Financial Officer of the Poxel SA since April 25, 2017. Prior to joining Poxel, Anne Renevot served as CFO of EOS Imaging where she played a key role in EOS successful IPO on Euronext Paris, which raised M. At EOS Imaging, Ms. Renevot helped to raise capital through private placements, equity lines and debt offerings. She was responsible for financial regulatory compliance, financial planning and communications, and she also held leading roles in the Company acquisitions and partnerships. Before her appointment at EOS Imaging, Ms. Renevot served at Cartier, a luxury goods company, as CFO of Cartier Joaillerie Manufacturing Division and as International Financial Controller. Earlier in her career, Ms. Renevot served as Manager at EY Audit and as a Division Controller at Legris Industries. Anne Renevot received a bachelor degree in finance from Audencia Business School in Nantes, France and a master degree in corporate finance from Ohio State University, Columbus, Ohio. since 2017.
| Tenure | 7 years |
| Phone | 33 4 37 37 20 10 |
| Web | https://www.poxelpharma.com |
Poxel SA Management Efficiency
The company has return on total asset
(ROA) of
(0.3038) % which means that it has lost $0.3038 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity
(ROE) of
(3.2337) %, meaning that it generated substantial loss on money invested by shareholders. Poxel SA's management efficiency ratios could be used to measure how well Poxel SA manages its routine affairs as well as how well it operates its assets and liabilities.
Poxel SA has accumulated 30.09
M in total debt with debt to equity ratio
(D/E) of 25.5, indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Poxel SA has a current ratio of 1.76, which is within standard range for the sector. Debt can assist Poxel SA until it has trouble settling it off, either with new capital or with free cash flow. So, Poxel SA's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Poxel SA sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Poxel to invest in growth at high rates of return. When we think about Poxel SA's use of debt, we should always consider it together with cash and equity.
Poxel SA, a biopharmaceutical company, develops drugs for metabolic diseases with a primary focus on type II diabetes. The company was founded in 2009 and is headquartered in Lyon, France. Poxel SA operates under Pharmaceuticals And Biosciences classification in France and is traded on Paris Stock Exchange. It employs 33 people. Poxel SA (POXEL) is traded on Euronext Paris in France and employs 55 people.
Management Performance
Poxel SA Leadership Team
Elected by the shareholders, the Poxel SA's board of directors comprises two types of representatives: Poxel SA inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Poxel. The board's role is to monitor Poxel SA's management team and ensure that shareholders' interests are well served. Poxel SA's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Poxel SA's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Quentin Durand, Chief VP | |
| Bolze PharmD, COO CoFounder | |
| Sylvie Bertrand, VP HR | |
| Pascale MD, CoFounder Affairs | |
| Noah MBA, Exec Operations | |
| Sophie HallakouBozec, CoFounder Communication | |
| Elizabeth MBA, Corp Relations | |
| MBA PharmD, CEO CoFounder | |
| David MD, Ex Officer | |
| Anne Renevot, Ex CFO | |
Poxel Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Poxel SA a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
Additional Tools for Poxel Stock Analysis
When running Poxel SA's price analysis, check to
measure Poxel SA's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Poxel SA is operating at the current time. Most of Poxel SA's value examination focuses on studying past and present price action to
predict the probability of Poxel SA's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Poxel SA's price. Additionally, you may evaluate how the addition of Poxel SA to your portfolios can decrease your overall portfolio volatility.